• Home
  • Company
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Advisors
  • Pipeline
    • AMHR2 and GM102
    • GamaMabs Pharma Technology
  • News and Publications
    • Press Releases
    • Scientific Publications
    • Others Publications
    • Careers
  • Contact us

Archives

GM102, a first-in-class monoclonal glyco-engineered antibody (Ab) targeting Anti-Mullerian – Hormone-Receptor II (AMHRII): safety and hints of activity in Granulosa Cell Tumors (GCT)

  • 6 December 2018
  • Scientific publications

ENA 2018 Poster #LBA15

Post navigation

← GM102, a low fucosylated anti-Müllerian Hormone type II Receptor (AMHRII) antibody promotes in vitro anti-tumoral activities of innate (macrophages) and adaptative (CD4+ and CD8+ T cells) immune cells GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human clinical study of murlentamab in advanced gynecological cancers →
© copyright 2021 - GamaMabs - All rights reserved Website by PICTAO